News >

Genomic Assays Answer Adjuvant Questions in Early-Stage Breast Cancer

Caroline Seymour
Published: Wednesday, Aug 07, 2019

Alan B. Astrow, MD, professor of medicine at Weil Cornell Medicine, chief of hematology and medical oncology, New York Methodist Hospital

Alan B. Astrow, MD

Questions on how to best use adjuvant chemotherapy and endocrine therapy, plus the need for extended endocrine therapy in women with early-stage hormone receptor (HR)–positive, HER2-negative breast cancer, have only been partly answered.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: PARP Inhibition in Breast Cancer: Practical Methods to Interpret and Apply the Evidence for Your PatientsAug 30, 20191.5
Provider and Caregiver Connection™: Addressing Patient Concerns in the Management of Premenopausal Breast CancerAug 31, 20192.0
Publication Bottom Border
Border Publication